Jagsonpal Pharmaceuticals Intrinsic Value
Jagsonpal Pharmaceuticals (JAGSNPHARM) median intrinsic value is ₹424.62 from 10 valuation models (range ₹69–₹491), vs current price ₹228.42 — +85.9% upside (Trading Below Calculated Value), margin of safety 46.2%. Check JAGSNPHARM market capitalization to track the company's total market size over time.
JAGSNPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Jagsonpal Pharmaceuticals intrinsic value across 10 models vs current price ₹228.42 — upside/downside and value range per method. For current market price and key ratios, visit Jagsonpal Pharmaceuticals stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹149.60 | ₹119.68 - ₹179.52 | -34.5% | EPS: ₹6.80, Sector P/E: 22x |
| Book Value Method | asset | ₹424.62 | ₹382.16 - ₹467.08 | +85.9% | Book Value/Share: ₹212.31, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹456.84 | ₹411.16 - ₹502.52 | +100.0% | Revenue/Share: ₹235.38, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹456.84 | ₹411.16 - ₹502.52 | +100.0% | EBITDA: ₹71.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹491.09 | ₹392.87 - ₹589.31 | +115.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹68.53 | ₹61.68 - ₹75.38 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹105.08 | ₹94.57 - ₹115.59 | -54.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹456.84 | ₹411.16 - ₹502.52 | +100.0% | ROE: 16.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹180.23 | ₹162.21 - ₹198.25 | -21.1% | EPS: ₹6.80, BVPS: ₹212.31 |
| Dividend Yield Method | dividend | ₹160.00 | ₹144.00 - ₹176.00 | -30.0% | DPS: ₹4.00, Target Yield: 2.5% |
JAGSNPHARM Intrinsic Value vs Market Price — All Valuation Models
Jagsonpal Pharmaceuticals fair value range ₹69–₹491 vs current market price ₹228.42 across 10 valuation models. See Jagsonpal Pharmaceuticals P/B ratio trends to compare market price against book value per share.
JAGSNPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Jagsonpal Pharmaceuticals median intrinsic value ₹424.62, current price ₹228.42 — Trading Below Calculated Value by 85.9%, margin of safety 46.2%.
What is the intrinsic value of JAGSNPHARM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Jagsonpal Pharmaceuticals (JAGSNPHARM) is ₹424.62 (median value). With the current market price of ₹228.42, this represents a +85.9% variance from our estimated fair value.
The valuation range spans from ₹68.53 to ₹491.09, indicating ₹68.53 - ₹491.09.
Is JAGSNPHARM undervalued or overvalued?
Based on our multi-method analysis, Jagsonpal Pharmaceuticals (JAGSNPHARM) appears to be trading below calculated value by approximately 85.9%.
JAGSNPHARM Financial Health — Key Ratios vs Industry Benchmarks
Jagsonpal Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.92 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.97x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JAGSNPHARM Cash Flow Quality — Operating & Free Cash Flow
Jagsonpal Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹47 Cr | ₹29 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹55 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹35 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹47 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹7 Cr | ₹-6 Cr | Positive Operating Cash Flow | 6/10 |